CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias.

Area of Science:

• Hematology
• Molecular Biology
• Cancer Research

Background:

• Acute Myeloid Leukemias (AMLs) often have poor prognoses, particularly high-risk cases that utilize stem cell gene regulatory programs.
• The transcription factor MECOM is frequently overexpressed in AMLs, driving aggressive disease, but its precise mechanism of action is unclear.

Purpose of the Study:

• To elucidate the mechanisms by which MECOM promotes aggressive AML phenotypes.
• To identify novel therapeutic targets within MECOM-driven oncogenic networks.

Main Methods:

• Engineered targeted protein degradation combined with functional genomic readouts.
• Investigated MECOM's role in repressing prodifferentiation gene regulatory programs.
• Analyzed a specific MECOM-bound cis-regulatory element downstream of CEBPA.

Main Results:

• MECOM was shown to promote malignant stem cell-like states by repressing differentiation pathways.
• A single cis-regulatory element, 42 kb downstream of CEBPA, was identified as essential for maintaining MECOM-driven leukemias.
• Targeted activation of this element induced AML cell differentiation and reduced leukemia burden in vivo.

Conclusions:

• MECOM drives aggressive AML by suppressing differentiation programs through specific regulatory elements.
• Targeting the identified CEBPA-associated regulatory element offers a potential therapeutic strategy for AML.
• The study demonstrates a powerful approach for dissecting oncogenic gene regulatory networks in cancer.